Physiomics inks contract extension with Numab Therapeutics

Mathematical modelling company Physiomics, which specialises in the development of oncology drugs and personalised medicine, confirmed a renewed contract with Numab Therapeutics on Tuesday.

The AIM-traded firm said the collaboration would revolve around PKPD modelling, assisting Numab's ongoing clinical programs.

It said the new agreement extended the relationship between the two firms, as Physiomics previously undertook similar work for Numab on the same medical asset.

The project was set to continue for the next two years of the clinical programme, the board confirmed.

“We are delighted that we have a further opportunity to support Numab with its exciting clinical pipeline and look forward to working once again with their talented team,” said chief executive officer Dr Jim Millen.

At 1513 BST, shares in Physiomics were down 2.05% at 0.955p.

Reporting by Josh White for Sharecast.com.